Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
9.893
Zitationen
18
Autoren
2016
Jahr
Abstract
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Ähnliche Arbeiten
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 · 30.895 Zit.
AJCC Cancer Staging Manual
2016 · 17.401 Zit.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 · 15.273 Zit.
The blockade of immune checkpoints in cancer immunotherapy
2012 · 13.542 Zit.
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
2012 · 12.520 Zit.
Autoren
Institutionen
- LungenClinic Grosshansdorf(DE)
- Hospital Universitario Insular de Gran Canaria(ES)
- Kingston General Hospital(CA)
- Westmead Hospital(AU)
- The University of Sydney(AU)
- Országos Korányi Tbc és Pulmonológiai Intézet(HU)
- Meir Medical Center(IL)
- Rabin Medical Center(IL)
- Tel Aviv University(IL)
- Cancer Trials Ireland(IE)
- St. James's Hospital(IE)
- Royal Marsden Hospital(GB)
- Royal Marsden NHS Foundation Trust(GB)
- MedStar Franklin Square Medical Center(US)
- Okayama University Hospital(JP)
- Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
- Sidney Kimmel Comprehensive Cancer Center(US)